The purpose of this study is to determine the effects that trabectedin has on Myxoid / round cell liposarcoma (MRCL) when it is given before the tumor is removed by surgery.
Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Primary Outcome Measures:
To determine the pathological complete response (pCR) rate with trabectedin in patients with localized myxoid / round cell liposarcoma (MRCL)
Secondary Outcome Measures:
Evaluate objective response rate by RECIST & contrast such responses with changes in radiological density & tumor pathology. Describe the incidence & severity of adverse events in this patient population; hypothesis-generating pharmacogenomic analyses
Estimated Enrollment: 22
Study Start Date: May 2007
Last Updated: January 29, 2009
CAMBIO DE DISCURSO : ADIÓS A LA SEGUNDA LÍNEA SCLC-ES EN EEUU Y EN EU ...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE /// SI NO EXISTIERA IMFORTE ... AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN /// IMFORTE EN EU DE UN TAM DE 600 MILLONES A UN MERCADO REAL MUCHO MENOR QUE PODRÍA SER DE TAN SOLO UNOS 85 MILLONES /// 2 DE OCTUBRE DE 2028 ... ES LA FECHA PARA LA POSIBLE ENTRADA DE GENÉRICOS DE LURBINECTEDIN ...